Skip to main content
Clinical Trials/ChiCTR2200063049
ChiCTR2200063049Not yet recruitingEarly Phase 1

山莨菪碱在 LO-PE 患者围术期应用对胎儿血氧分压及 apgar 评分的影响

个人1 site in 1 country120 target enrollmentStarted: August 15, 2022Last updated:

Trial Snapshot

Phase
Early Phase 1
Status
Not yet recruiting
Sponsor
Enrollment
120
Locations
1
Primary Endpoint
胎儿血氧分压

Study Overview

Brief Summary

本研究拟通过观察新生儿血氧分压及 apgar 评分等指标变化,以评价山莨菪碱在晚发型子痫前期应用的有效意义,为临床诊疗中合并有晚发型子痫前期产妇的围术期麻醉前用药及管理提供参考。

Study Design

Study Type
干预性研究
Primary Purpose
随机平行对照
Masking
双盲法

Eligibility Criteria

Ages
21 to 45 (—)
Sex
Female

Inclusion Criteria

  • 符合《妇产科学(第七版)》诊断标准首次确诊为妊娠期高血压疾病中晚发型子痫前期产妇;
  • ASA II-III 级、单胎、无椎管内麻醉禁忌。

Exclusion Criteria

  • 合并其他妊娠期并发症者;
  • 合并有严重的心、脑、肾等重要脏器器质性疾病;
  • 有颅内压增高、青光眼、幽门梗阻等禁忌症;

Arms & Interventions

实验组

静脉给予山莨菪碱

对照组

静脉给予生理盐水

Outcomes

Primary Outcomes

胎儿血氧分压

Time Frame: 胎儿取出后断脐

apgar 评分

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
个人

Study Sites (1)

Loading locations...

Similar Trials